Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥5.72, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total returns to shareholders of 38% over the past three years. Announcement • Jun 30
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 Reported Earnings • Apr 25
First quarter 2026 earnings released: CN¥0.003 loss per share (vs CN¥0.01 loss in 1Q 2025) First quarter 2026 results: CN¥0.003 loss per share (improved from CN¥0.01 loss in 1Q 2025). Revenue: CN¥59.6m (down 7.7% from 1Q 2025). Net loss: CN¥2.59m (loss narrowed 67% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Apr 25
Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2026 Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2026, at 14:30 China Standard Time. Location: 3F, No. 36, Nanbin West Road, Lihai Town, Binhai New City, Shaoxing, Zhejiang China Announcement • Mar 31
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥7.18, the stock trades at a trailing P/E ratio of 39.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 57% over the past three years. Board Change • Feb 14
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Board Secretary & Director Hao Zong was the last director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 31
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥7.38, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total returns to shareholders of 37% over the past three years. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥9.06, the stock trades at a trailing P/E ratio of 50.1x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total returns to shareholders of 72% over the past three years. Reported Earnings • Oct 29
Third quarter 2025 earnings released: CN¥0.011 loss per share (vs CN¥0.012 loss in 3Q 2024) Third quarter 2025 results: CN¥0.011 loss per share (improved from CN¥0.012 loss in 3Q 2024). Revenue: CN¥76.2m (down 10% from 3Q 2024). Net loss: CN¥7.98m (loss narrowed 11% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improves as stock rises 37% After last week's 37% share price gain to CN¥7.75, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total returns to shareholders of 46% over the past three years. Announcement • Sep 30
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 New Risk • Sep 06
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). New Risk • Jul 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (22% increase in shares outstanding). Announcement • Jul 02
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 Announcement • Jun 27
Zhejiang Zhongqingda Construction Industry Co., Ltd. completed the acquisition of Shaoxing Xingya Pharmaceutical Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370). Zhejiang Zhongqingda Construction Industry Co., Ltd. agreed to acquire Shaoxing Xingya Pharmaceutical Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for approximately CNY 180 million on March 31, 2025. A cash consideration of CNY 48.73 million and of CNY 126.27 million will be paid by Zhejiang Zhongqingda Construction Industry Co., Ltd. As part of consideration, CNY 126.27 million is paid towards common equity and CNY 48.73 million is paid towards non-convertible debt of Shaoxing Xingya Pharmaceutical Co., Ltd.
For the period ending December 31, 2024, Shaoxing Xingya Pharmaceutical Co., Ltd. reported total revenue of CNY -2.8 million and net loss of CNY 4.42 million. As of December 31, 2024, Shaoxing Xingya Pharmaceutical Co., Ltd. reported total assets of CNY 28.12 million and net liabilities of CNY 21.1 million.
The transaction is subject to approval of merger agreement by target board. The deal has been approved by the board.
Zhejiang Zhongqingda Construction Industry Co., Ltd. completed the acquisition of Shaoxing Xingya Pharmaceutical Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) on June 25, 2025. On completion, Zhejiang Yatai Pharmaceutical Co., Ltd had received the full payment for the equity transfer price and debt repayment totaling to CNY 175 million. New Risk • May 12
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 48% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (22% increase in shares outstanding). Reported Earnings • Apr 30
Full year 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.02 loss in FY 2023) Full year 2024 results: EPS: CN¥0.05 (up from CN¥0.02 loss in FY 2023). Revenue: CN¥405.2m (down 3.7% from FY 2023). Net income: CN¥34.2m (up CN¥46.1m from FY 2023). Profit margin: 8.5% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Apr 25
Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2025 Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2025, at 14:00 China Standard Time. Location: 3F, No. 36, Nanbin West Road, Lihai Town, Binhai New City, Shaoxing, Zhejiang China Announcement • Apr 19
Zhejiang Yatai Pharmaceutical Co., Ltd. Approves Board Elections Zhejiang Yatai Pharmaceutical Co., Ltd. at its extraordinary general meeting held on 15 April 2025 approved the election of Cen Jianwei and Xu Wei as non-independent director. The company approved the election of Lv Haizhou as independent director. Announcement • Mar 31
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 New Risk • Jan 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Announcement • Dec 31
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.012 loss per share (vs CN¥0.028 loss in 3Q 2023) Third quarter 2024 results: CN¥0.012 loss per share (improved from CN¥0.028 loss in 3Q 2023). Revenue: CN¥84.9m (up 5.2% from 3Q 2023). Net loss: CN¥8.93m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 New Risk • Sep 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding). Announcement • Sep 12
Ningbo Heyi Culture Media Co., Ltd agreed to acquire Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for CNY 1.4 million. Ningbo Heyi Culture Media Co., Ltd agreed to acquire Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for CNY 1.4 million on September 9, 2024. As part of consideration, CNY 1 is paid towards common equity and CNY 1.46 million is paid towards non-convertible debt of Shanghai Xingaofeng Newsummit Biopharma Co., Ltd.
As of June 30, 2024, Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. reported total assets of CNY 0.38 million and net liabilities of CNY 1.07 million.
The transaction is subject to approval of merger agreement by target board. The deal has been approved by the board. Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.049 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.018 (down from CN¥0.049 in 2Q 2023). Revenue: CN¥109.2m (up 12% from 2Q 2023). Net income: CN¥8.47m (down 62% from 2Q 2023). Profit margin: 7.8% (down from 23% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Aug 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Announcement • Jun 29
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Reported Earnings • Apr 01
Full year 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.25 loss in FY 2022) Full year 2023 results: CN¥0.02 loss per share (improved from CN¥0.25 loss in FY 2022). Revenue: CN¥420.6m (up 13% from FY 2022). Net loss: CN¥11.9m (loss narrowed 91% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Dec 29
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Mar 30, 2024 New Risk • Nov 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (5.2% increase in shares outstanding). New Risk • Nov 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 29
Third quarter 2023 earnings released: CN¥0.028 loss per share (vs CN¥0.05 loss in 3Q 2022) Third quarter 2023 results: CN¥0.028 loss per share (improved from CN¥0.05 loss in 3Q 2022). Revenue: CN¥80.7m (up 11% from 3Q 2022). Net loss: CN¥18.5m (loss narrowed 37% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 28, 2023 Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 loss in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.049 (up from CN¥0.05 loss in 2Q 2022). Revenue: CN¥97.6m (up 4.7% from 2Q 2022). Net income: CN¥22.4m (up CN¥45.4m from 2Q 2022). Profit margin: 23% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 26
Full year 2022 earnings released: CN¥0.25 loss per share (vs CN¥0.43 loss in FY 2021) Full year 2022 results: CN¥0.25 loss per share (improved from CN¥0.43 loss in FY 2021). Revenue: CN¥373.4m (up 19% from FY 2021). Net loss: CN¥132.7m (loss narrowed 42% from FY 2021). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Nov 16
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. Member of the Supervisory Huaying Zhou is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 28
Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.10 loss in 3Q 2021) Third quarter 2022 results: CN¥0.05 loss per share (improved from CN¥0.10 loss in 3Q 2021). Revenue: CN¥72.6m (up 11% from 3Q 2021). Net loss: CN¥29.5m (loss narrowed 43% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 29
Second quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 2Q 2021) Second quarter 2022 results: CN¥0.05 loss per share (down from CN¥0.04 loss in 2Q 2021). Revenue: CN¥93.2m (up 27% from 2Q 2021). Net loss: CN¥23.1m (loss widened 16% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • May 07
Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022 Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022, at 14:00 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee; to consider 2021 annual accounts; to consider 2021 annual report and its summary; to consider 2021 profit distribution plan; and to consider other matters. Reported Earnings • May 02
First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 1Q 2021) First quarter 2022 results: CN¥0.05 loss per share (down from CN¥0.04 loss in 1Q 2021). Revenue: CN¥68.3m (down 14% from 1Q 2021). Net loss: CN¥28.9m (loss widened 21% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Member of the Supervisory Board Da Xu is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 19
Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments Zhejiang Yatai Pharmaceutical Co., Ltd. at its Extraordinary General Meeting held on 15 April 2022, approved the election of Song Lingjie, Huang Xiaoming, Fu Cai, Song Lingbo, Huang Wei and Zhou Yajian as non-independent directors. The company also approved the election of Lv Haizhou, Liu Yuehui and Cai Min as independent directors and Xu Da and Zhou Huaying as non-employee supervisors. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥5.25, the stock trades at a trailing P/E ratio of 70.4x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment deteriorated over the past week After last week's 28% share price decline to CN¥5.63, the stock trades at a trailing P/E ratio of 75.5x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total loss to shareholders of 39% over the past three years. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥5.25, the stock trades at a trailing P/E ratio of 70.4x. Average trailing P/E is 38x in the Pharmaceuticals industry in China. Total loss to shareholders of 70% over the past three years. Reported Earnings • Oct 27
Third quarter 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.098 loss in 3Q 2020) The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: CN¥65.6m (down 36% from 3Q 2020). Net loss: CN¥51.2m (loss narrowed 2.8% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 30
Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 2Q 2020) The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: CN¥73.6m (down 33% from 2Q 2020). Net loss: CN¥20.0m (loss narrowed 32% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. Reported Earnings • May 01
First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020) The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: CN¥79.0m (down 47% from 1Q 2020). Net loss: CN¥23.9m (loss narrowed 3.5% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 27
Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥3.86 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥514.9m (down 27% from FY 2019). Net income: CN¥27.3m (up CN¥2.10b from FY 2019). Profit margin: 5.3% (up from net loss in FY 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Announcement • Jan 28
Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index Is New 90 Day High Low • Jan 13
New 90-day low: CN¥3.07 The company is down 39% from its price of CN¥5.04 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥3.62 The company is down 31% from its price of CN¥5.27 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: CN¥4.42 The company is down 28% from its price of CN¥6.11 on 03 September 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period. Is New 90 Day High Low • Oct 21
New 90-day low: CN¥4.77 The company is down 4.0% from its price of CN¥4.97 on 23 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Announcement • Oct 20
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report Q3, 2020 results on Oct 28, 2020 Announcement • Aug 11
Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Zhejiang Yatai Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020 
